Login or sign up
For business
Average ratingGreat
4.2/ 5

Based on 13 reviews

538%
438%
323%
20%
10%
Ask AI

Questions about Ambit

Based on 13 reviews, listing data and website checks ยท updated 2 days ago

What is Ambit?

Ambit Biosciences is a privately-held biopharmaceutical company based in San Diego, CA, that discovers and develops small molecule kinase inhibitors. Their lead compound, quizartinib (also known as AC220), is an orally administered FLT3 inhibitor currently under clinical investigation for relapsed or refractory AML. They are developing this drug in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications.

Where is Ambit located and how can I reach them?

The company is located at 11080 Roselle St. in San Diego, CA, approximately 20 miles north of the San Diego Airport and 1ยฝ to 2 hours south of LAX. Their main number is 858.334.2100 and their facsimile is 858.334.2192. They also provide specific directions from both the San Diego Airport and LAX via Interstate 5 and local roads like Sorrento Valley Road and Carmel Mountain Road.

What products or programs are currently in Ambit's pipeline?

According to their website, Ambit has a product pipeline currently in development that includes three programs: quizartinib (FLT3), AC410 (JAK2), and a CSF1R Program. They also mention CEP32496 (BRAF) as part of their product development efforts. These programs aim to inhibit validated kinase targets for treating unmet medical needs in oncology, autoimmune, and inflammatory diseases.

What do reviewers say about Ambit's services and team?

Some reviewers on Trustburn praise Ambit for their remarkable expertise in the biotech industry and their user-friendly, informative website at ambitbio.com. They also highlight the team's responsiveness, professionalism, and exceptional services, with many noting that the team is always available to address concerns and provide guidance.

What major clinical trial did Ambit initiate?

Ambit initiated a Phase 3 clinical trial of quizartinib in April 2014 for patients with acute myeloid leukemia (AML) who express a genetic mutation in FLT3 (FLT3-ITD positive). The trial plans to enroll approximately 326 patients who will be randomized 2:1 to quizartinib monotherapy or salvage chemotherapy, with a single interim analysis planned.

What is Ambit's second drug candidate?

The company's second drug candidate is AC410, a potent and selective, orally-administered small molecule inhibitor of Janus kinase 2 (JAK2). This compound has potential utility for the treatment of autoimmune and inflammatory diseases, complementing their oncology-focused quizartinib program.

How does Ambit's website support its customers?

Ambit's website, ambitbio.com, is described by reviewers as user-friendly and informative, offering valuable insights into their services and pipeline. The site includes sections on their product pipeline, scientific advisors, and directions to their corporate headquarters, making it easy for visitors to navigate.

What specific expertise does Ambit offer to its clients?

The company offers services ranging from profiling services to clinical development expertise, positioning itself as a 'Kinase Partner of Choice.' Their approach leverages internal kinase expertise to discover, optimize, and develop a sustainable pipeline of small molecule kinase inhibitors.

How does Ambit structure its scientific strategy?

Ambit's strategy involves leveraging their kinase expertise to create a sustainable pipeline of small molecule kinase inhibitors. They focus on discovering and optimizing compounds that target validated kinase drivers for diseases in oncology, autoimmune, and inflammatory categories.

What qualities do customers appreciate about Ambit's team?

Some reviewers note that Ambit's team is highly knowledgeable and efficient, consistently delivering high-quality work on time. They also mention that the team is dedicated and always ready to assist, which contributes to the positive experiences reported by customers.

What diseases is Ambit targeting with its current pipeline?

Ambit's clinical pipeline includes quizartinib for AML, AC410 for autoimmune and inflammatory diseases, and AC708 for similar conditions. They are also developing CEP32496 (BRAF) and have a dedicated CSF1R program, showing a broad focus on kinase inhibition across multiple disease areas.

How does Ambit collaborate with other companies?

Ambit collaborates with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors. This partnership allows them to leverage external resources while maintaining internal discovery and optimization capabilities for their kinase inhibitor programs.

How does Ambit facilitate communication with different stakeholders?

The company provides detailed directions for visitors coming from the San Diego Airport or LAX, ensuring easy access to their corporate headquarters at 11080 Roselle St. They also offer contact forms for investors, media, business development, and careers, facilitating communication with various stakeholders.

How is Ambit rated on Trustburn?

On Trustburn, Ambit has a rating of 4.2 out of 5 based on 13 reviews.

Is Ambit on social media?

Ambit has official profiles on Linkedin.

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website โ€” a simple way to convert your visitors into customers.

Get the widget for your site →

About Ambit

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Categories
Biotechnology